SCHEMBL19448679

SCHEMBL19448679

CC(=O)Nc1ccccc1-c1ccccc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HPGD P15428 2/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
MAOA P21397 1/20 0.51
PARP14 Q460N5 4/20 0.51
CYP2C19 P33261 2/20 0.50
HDAC1 Q13547 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC2 Q92769 1/20 0.50
ABCG2 Q9UNQ0 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326388 0.88 ALDH1A1 (0.65) ALDH1A1HPGDKDM4ESMN1; SMN2MAOA
SCHEMBL463597 0.84 ALDH1A1 (0.61) ALDH1A1HPGDCYP2C19HDAC1HDAC3
SCHEMBL29904721 0.84 ALDH1A1 (0.61) ALDH1A1HPGDCYP2C19HDAC1HDAC3
SCHEMBL17796923 0.83 HDAC3 (0.50) ALDH1A1HPGDKDM4EHDAC1CYP2C9
Hydrochloric Acid SCHEMBL11503558 0.82 HDAC1 (0.59) ALDH1A1HPGDSMN1; SMN2CYP2C19HDAC1
SCHEMBL25066473 0.82 HDAC3 (0.45) ALDH1A1HPGDKDM4ESMN1; SMN2HDAC1
SCHEMBL20458594 0.82 ALDH1A1 (0.59) ALDH1A1HPGDKDM4ESMN1; SMN2MAOA
SCHEMBL16429257 0.81 ALDH1A1 (0.57) ALDH1A1HPGDKDM4ESMN1; SMN2MAOA
SCHEMBL7455097 0.79 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EMAOACYP2C19
SCHEMBL5623725 0.79 ALDH1A1 (0.71) ALDH1A1HPGDKDM4ESMN1; SMN2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170305846-A1 2,2' -DIAMINOBIARYLS HAVING A PHTHALOYL GROUP OR SUCCINOYL GROUP EVONIK DEGUSSA GMBH (DE) 2017-10-26 US disclosed
US-20170305846-A1 2,2' -DIAMINOBIARYLS HAVING A PHTHALOYL GROUP OR SUCCINOYL GROUP EVONIK DEGUSSA GMBH (DE) 2017-10-26 US disclosed
US-20170298013-A1 2,2' -DIAMINO BIARYLS WITH TWO SECONDARY AMINES AND PRODUCTION THEREOF BY ELECTROCHEMICAL COUPLING EVONIK DEGUSSA GMBH (DE) 2017-10-19 US disclosed
US-20170298013-A1 2,2' -DIAMINO BIARYLS WITH TWO SECONDARY AMINES AND PRODUCTION THEREOF BY ELECTROCHEMICAL COUPLING EVONIK DEGUSSA GMBH (DE) 2017-10-19 US disclosed
US-20170291871-A1 2,2' -DIAMINOBIARYLS HAVING ONE PRIMARY AND ONE SECONDARY AMINE EVONIK DEGUSSA GMBH (DE) 2017-10-12 US disclosed
US-20170291871-A1 2,2' -DIAMINOBIARYLS HAVING ONE PRIMARY AND ONE SECONDARY AMINE EVONIK DEGUSSA GMBH (DE) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298013-A1 2,2' -DIAMINO BIARYLS WITH TWO SECONDARY AMINES AND PRODUCTION THEREOF BY ELECTROCHEMICAL COUPLING PM20D2, XDH, DAO ALDH1A1 408/4885HPGD 3023/4885KDM4E 2129/4885
US-20170291871-A1 2,2' -DIAMINOBIARYLS HAVING ONE PRIMARY AND ONE SECONDARY AMINE SAT1, AOC1, DDT ALDH1A1 480/4885HPGD 4484/4885KDM4E 3159/4885
US-20170305846-A1 2,2' -DIAMINOBIARYLS HAVING A PHTHALOYL GROUP OR SUCCINOYL GROUP SUCLA2, SPATS2L, SUCLG2 ALDH1A1 673/4885HPGD 3461/4885KDM4E 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.